This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Cristina d'Abramo, Ph.D.
Assistant Investigator, The Litwin-Zucker Research Center for the Study of Alzheimer's Disease at The Feinstein Institute for Medical Research, North Shore - LIJ


Dr. d’Abramo’s interest on Alzheimer’s disease started 15 years in the Laboratory of Experimental Medicine (Pathology) at the University of Genova. In those early years, the lab was focusing on aging cell biology and on the relationship between oxidative stress, activation of kinases (e.g. PKC) and the metabolism of APP.

During her Ph.D. training at the University of Genova, Dr. d’Abramo had the privilege to join Dr. Peter Davies’ laboratory at Albert Einstein College of Medicine as a visiting scientist, getting to learn more about the role of tau pathology in Alzheimer’s disease.

After defending her PhD thesis in Genova, Dr. d’Abramo was offered a Postdoctoral position by Dr. Davies in the Alzheimer’s disease and Memory Disorder Center at the Feinstein Institute for Medical Research (Northwell Health). First as a Postdoctoral trainee and later as an Institute Scientist, Dr. d’Abramo had the chance to gain considerable experience in working with rodent animal models of tau pathology together with a continuous training in cell and molecular biology. Moreover, learning how to produce and handle tau monoclonal antibodies gave her the opportunity to contribute to immunotherapy experiments and development of new tau assays, which turned into peer-reviewed publications.

Dr. d’Abramo is an Assistant Professor at the The Litwin-Zucker Research Center for the Study of Alzheimer's Disease (The Feinstein Institute for Medical Research, Northwell Health, NY). Her team is currently working on the generation of new recombinant tau antibodies to be used in passive immunotherapy in AD, engineering new strategies to deliver them to the brain.

Agenda Sessions

  • Tau Antibodies to Target Tau in Alzheimer’s Disease: From Proof of Concept to Translational Strategies